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Abstract
Human pluripotent stem cells (hPSCs), including both embryonic and induced pluripotent stem 
cells, possess the unique ability to readily differentiate into any cell type of the body, including 
cells of the retina. Although previous studies have demonstrated the ability to differentiate hPSCs 
to a retinal lineage, the ability to derive retinal ganglion cells (RGCs) from hPSCs has been 
complicated by the lack of specific markers with which to identify these cells from a pluripotent 
source. In the current study, the definitive identification of hPSC-derived RGCs was accomplished 
by their directed, stepwise differentiation through an enriched retinal progenitor intermediary, with 
resultant RGCs expressing a full complement of associated features and proper functional 
characteristics. These results served as the basis for the establishment of induced pluripotent stem 
cells (iPSCs) from a patient with a genetically inherited form of glaucoma, which results in 
damage and loss of RGCs. Patient-derived RGCs specifically exhibited a dramatic increase in 
apoptosis, similar to the targeted loss of RGCs in glaucoma, which was significantly rescued by 
the addition of candidate neuroprotective factors. Thus, the current study serves to establish a 
method by which to definitively acquire and identify RGCs from hPSCs and demonstrates the 
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ability of hPSCs to serve as an effective in vitro model of disease progression. Moreover, iPSC-
derived RGCs can be utilized for future drug screening approaches to identify targets for the 
treatment of glaucoma and other optic neuropathies.
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Introduction
Human pluripotent stem cells (hPSCs) offer the unique and unprecedented ability to study 
the differentiation of specific cellular lineages, particularly at those stages of development 
that would otherwise be inaccessible to investigation. As such, they have been demonstrated 
to serve as powerful in vitro models for human ontogenesis1,2. When derived from specific 
patient populations, human induced pluripotent stem cells (iPSCs) are capable of serving as 
in vitro models of disease progression3-8, effectively bridging the gap between basic and 
translational research. Among the diseases that may be effectively modeled with iPSCs, 
those affecting the retina have been of particular interest4,5,9-11 as a number of methods exist 
to derive all of the major cell types of the retina4,12-20, and a relative lack of effective 
treatments and cures exist for many blinding disorders.
While many previous studies have focused upon the ability to derive and utilize retinal cells 
such as photoreceptors and retinal pigment epithelium4,5,12-21, retinal ganglion cells (RGCs) 
have been largely overlooked to date. As the projection neurons of the retina, RGCs 
effectively serve as the connection between the eye and the brain. Furthermore, RGCs are 
the predominant affected cell type in a group of diseases known as optic neuropathies, the 
most common of which is glaucoma with a current incidence of over 60 million individuals 
worldwide22,23. Within the context of the retina, RGCs are often identified by the expression 
of a limited set of markers that are specific to these cells. However, when derived from a 
pluripotent cell source, these markers are no longer specific for RGCs as they are expressed 
elsewhere in the nervous system. To date, the detailed description and utilization of hPSC-
derived RGCs has been largely lacking likely due to the shortage of reliable markers with 
which to definitively identify these cells without the assurance of a retinal lineage, although 
previous studies have demonstrated the ability to derive cells with RGC-like 
characteristics4,12,14-18,24-28. Thus, a systematic, detailed analysis of these cells is warranted 
in order to serve as a comprehensive in vitro model of RGC development, as well as the 
application of patient-derived RGCs for disease modeling.
To this end, efforts were undertaken to comprehensively detail the differentiation of RGCs, 
with subsequent application of these approaches to a glaucoma patient-derived line of 
iPSCs. Lines of hPSCs were directed to differentiate in a stepwise fashion specifically 
toward a retinal lineage, and highly enriched populations of retinal progenitor cells were 
readily identified and isolated, yielding a highly purified population. Upon further 
differentiation of these retinal progenitor cells, presumptive RGCs were identifiable within a 
total of 40 days of differentiation and were characterized for morphological, phenotypic, and 
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physiological features of native RGCs. These cells were found to express all of the observed 
features associated with RGCs and importantly, the possibility was excluded to have 
differentiated into alternate lineages bearing similar phenotypic markers. Furthermore, 
hPSC-derived cells possessed expected physiological properties of RGCs29. Following the 
conclusive identification and characterization of hPSC-derived RGCs, similar approaches 
were undertaken for iPSCs derived from a glaucoma patient possessing an E50K mutation in 
the Optineurin (OPTN) gene, responsible for some familial forms of glaucoma30-36. These 
cells were differentiated to an RGC fate, at which point their ability to serve as an in vitro 
model for studies of disease progression and drug screening were tested. The results of these 
studies support a role for hPSCs as an effective in vitro model for human RGC development 
and functionality, as well as for use in studies of cellular mechanisms underlying disease 
progression in optic neuropathies.
Materials and Methods
Maintenance of hPSCs
hPSCs were maintained as previously described15,17. Briefly, three lines of control human 
pluripotent stem cells (H9, H737 and miPS238) were used, and three lines of patient-derived 
induced pluripotent stem cells from an OPTN E50K patient were derived. All cell lines were 
maintained in the pluripotent state with mTeSR1 medium (Stemcell Technologies) on 
matrigel-coated 6-well plates. Cells were passaged upon reaching confluency of 
approximately 70%. Areas of spontaneous differentiation were initially identified by their 
distinct appearance and were mechanically removed. Colonies of hPSCs were then 
enzymatically lifted with dispase (2 mg/ml) for approximately 15 minutes and passaged at a 
ratio of 1:6 onto freshly-coated matrigel plates in mTeSR1 medium. Passaging of hPSCs 
typically occurred every 4-5 days.
Differentiation of hPSCs
Differentiation of hPSCs to a retinal lineage was performed with modifications to previously 
established protocols15. Briefly, embryoid bodies (EBs) were generated from 
undifferentiated colonies of hPSCs by lifting adherent cultures with dispase. EBs were 
gradually transitioned into Neural Induction Medium (NIM) consisting of DMEM/F12 (1:1), 
N2 supplement, MEM nonessential amino acids and heparin (2 μg/ml). After a total of 7 
days of differentiation, EBs were plated onto uncoated 6-well plates and induced to adhere 
by the addition of 10% FBS overnight. The next day, NIM was replaced without FBS and 
medium was subsequently changed every other day until day 16. At this point, cells were 
lifted from plates by mechanical scraping or pipetting to dislodge colonies and generate 
neurospheres in suspension cultures. Neurospheres were maintained in Retinal 
Differentiation Medium (RDM) consisting of DMEM/F12 (3:1), MEM non-essential amino 
acids, B27 supplement, and antibiotics. Medium was replenished every 2-3 days thereafter 
until the desired day of differentiation was reached. At this point, retinal neurospheres were 
isolated according to previously established protocols4,15,17,18,39 based upon morphological 
cues exhibited by the neurospheres. As indicated in some experiments, OPTN iPSC-derived 
neurospheres were treated with either BDNF (100 ng/mL) or PEDF (100 ng/ml) from day 50 
to day 70 of differentiation. Neurospheres were either harvested for RNA analysis, or 
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partially dissociated with accutase and plated onto poly-L-ornithine/laminin-coated 
coverslips for immunocytochemical analysis.
Reprogramming of fibroblasts to iPSCs
The generation of OPTN glaucoma patient iPSCs was performed using mRNA 
reprogramming strategies as previously described40. Synthetic mRNAs with a microRNA 
booster kit (Stemgent) were introduced into OPTN fibroblasts through the use of Stemfect 
Transfection Reagent following manufacturers instructions. mRNAs were transfected daily 
for a total of 14 days. Within the first 20 days of reprogramming, some fibroblasts began to 
lose their elongated morphology and displayed the typical tightly packed morphology of iPS 
cell colonies. Individual colonies of prospective iPSCs were identified, manually isolated, 
and clonally expanded to yield lines of patient-specific iPSCs. Newly established lines of 
iPSCs were maintained as described above.
RT-PCR
RNA was isolated from retinal neurospheres using the Picopure RNA Isolation Kit 
(LifeTechnologies), with subsequent cDNA synthesis achieved utilizing the iScript cDNA 
synthesis kit (BioRad). PCR analysis was accomplished using Go-Taq PCR Master Mix 
(Promega), while qPCR analysis was performed with SybrGreen (Life Technologies). For 
RTPCR experiments, reactions were performed for 35 cycles and products were run on 2% 
agarose gels. Primers for RT-PCR and qRT-PCR analysis can be found in Supplemental 
Tables 1 and 2.
Immunocytochemistry and Data Quantification
Samples were collected at indicated timepoints of differentiation and plated on poly-L-
orinithine and laminin-coated coverslips. Cells were fixed in a 4% paraformaldehyde and 
phosphate buffer (PBS) solution for 30 minutes. Alternatively, neurospheres were processed 
for cryostat sectioning as indicated. For this purpose, neurospheres were fixed in 4% 
paraformaldehyde and PBS for 45 minutes and then introduced into a 20% sucrose solution 
in PBS for equilibration overnight at 4 degrees. The following day, sucrose solution was 
aspirated and changed to a 30% sucrose solution at 4°C. Following equilibration, 
neurospheres were embedded in OCT, frozen in dry ice and stored at −80°C until sectioning. 
Cryostat sections were cut at a thickness of 10 microns and stored at −80°C until use for 
immunocytochemistry.
For immunostaining of both coverslips and cryostat slides, samples were initially washed 
three times with PBS and permeabilized with 0.2% Triton X-100 for 10 minutes at room 
temperature. 10% donkey serum in PBS was used as a blocking agent for one hour at room 
temperature and primary antibodies (Supplemental Table 3) were applied in a solution 
consisting of 5% donkey serum and 0.1% Triton X-100 overnight at 4°C. The next day, 
samples were washed with PBS and 10% donkey serum blocking agent was applied for 10 
minutes at room temperature. Samples were treated with secondary antibodies diluted in a 
5% donkey serum and 0.1% Triton X-100 solution for one hour at room temperature, 
followed by 3 washes with PBS. Samples were mounted onto slides and cells were imaged 
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with either a Leica DM5500 fluorescence microscope or an Olympus Fluoview 2000 
confocal microscope.
Quantification of cell counts was performed with Image-J software using immunostained 
samples. For each experimental condition, three different lines of hPSCs were utilized. 
Within these different cell lines, a minimum of three images were collected from at least 
three separate experiments performed at different passage number from each cell line. Each 
image was quantified to calculate the percentage of BRN3-positive cells, as well as the 
abundance of activated caspase-3 expression relative to the total number of BRN3-positive 
cells. ANOVA statistical analyses or student's t-tests were performed with Prism software 
(Graphpad) to determine statistically significant differences at a p-value of less than 0.05. 
Size of the Golgi complex was determined by GM130 staining similar to previous 
reports41-43 by calculating the total area of GM130-positive staining utilizing ImageJ 
software, and then dividing this number by the total number of DAPI-positive nuclei. A 
minimum of three samples were analyzed per experiment to obtain the average Golgi area 
per cell. A student's t-test was used to determine statistical significance using Prism 
software, and significant differences were identified at a p value less than 0.05.
Electrophysiology
Whole-cell patch-clamp recordings were carried out at room temperature (21°C) as 
previously described44 using an EPC-10 amplifier and the Pulse8.31 program (HEKA, 
Lambrecht/Pfalz, Germany). Fire-polished electrodes were fabricated from borosilicate 
capillary glass (1.2-mm outer diameter, 0.69-mm inner diameter; Sutter Instrument Co., 
Novato, CA) using a P-97 puller (Sutter Instrument Co., Novato, CA). After filling with the 
intracellular solution containing (in mM): KCl 140, MgCl2 5, EGTA 5, CaCl2 2.5, Hepes 
10, ATP 4, GTP 0.3, Phosphocreatine 8, pH7.3 (adjusted with KOH), the access resistance 
of electrode pipettes ranged between 4 and 5 MΩ. The bathing solution contained (in mM): 
NaCl 140, MgCl2 1, KCl 5, CaCl2 2, Hepes 10, Glucose 10, pH7.3 (adjusted with NaOH). 
After establishing the whole-cell recording configuration, cells were allowed to stabilize for 
2-3 minutes in current-clamp mode before initiating ramp current injection to measure 
action potential activity. Cells were held at −100 mV to stabilize for 5 minutes in voltage-
clamp mode before applying depolarizing voltage steps to measure potassium and sodium 
currents. A -P/4 subtraction protocol was used to remove linear leak current and capacitance 
artifact for all voltage clamp recordings. Voltage errors were minimized using more than 
80% series resistance compensation. Membrane currents were filtered at 5 kHz and sampled 
at 20 kHz. Tetrodotoxin (TTX, 5 μM) and tetraethylammonium (TEA, 100 mM) stock 
solutions were made using the bathing solution. TTX or TEA was diluted into a 300 μl 
recording chamber to achieve the final concentration.
Results
Identification of hPSC-Derived Retinal Ganglion Cells
The definitive identification of RGCs from a pluripotent source has been complicated by the 
lack of specific markers to identify these cells. The expression of the transcription factor 
BRN3 has been widely utilized to identify cells with RGC-like characteristics4,12,14-18,24-26. 
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However, when derived from hPSCs, such markers lose their specificity as BRN3 is also 
expressed in other cell types of the central nervous system, particularly hair cells of the 
auditory system45 as well as somatosensory neurons46. Thus, to conclusively establish the 
RGC nature of these cells, their derivation and identification necessitates the detailed 
stepwise differentiation through early neural and retinal progenitor intermediaries.
To this end, initial efforts were focused upon the differentiation and definitive identification 
of hPSC-derived RGCs. As a starting point, hPSCs were directed to differentiate to an optic 
vesicle-like stage of retinogenesis as previously described4,15,17,18,25, at which point highly 
enriched populations of CHX10-positive retinal progenitor cells comprised 50.02 ± 1.95% 
of all neurospheres. These retinal populations were readily identified and isolated apart from 
their non-retinal forebrain counterparts based upon morphological cues (Figure 1A-C), 
allowing for the subsequent classification of further differentiated phenotypes to the retinal 
lineage. Within 40 total days of differentiation, enriched populations of optic vesicle-like 
retinal neurospheres began to express BRN3 as well as a compliment of other retinal-
associated transcription factors when analyzed by RT-PCR (Figure 1D). Conversely, no 
expression of genes characteristic of the auditory45 and somatosensory46 lineages was 
detected. Taken together, these results confirm the retinal phenotype associated with these 
BRN3-positive cells. Immunocytochemistry analysis further confirmed the expression of 
BRN3 with other markers of the retinal lineage (Figure 1E-G). Specifically, BRN3 
expression was often found colocalized with markers typically associated with retinal 
progenitor cells and some RGCs such as PAX6 and SIX6. However, colocalization of BRN3 
with markers indicative of other retinal cell types such as Recoverin was not observed 
(Figure S1).
The temporal birth order of specific retinal cell types has been well characterized in vivo, 
with retinal progenitors giving rise to RGCs and cone photoreceptors early while rods and 
Müller glia emerge later47,48. Through immunocytochemical analysis, early stages of this 
stepwise progression to an RGC fate could be observed (Figure 2A), with PAX6-positive 
neural progenitors the first stage in this differentiation process. Following the identification 
and isolation of retinal neurospheres, robust differentiation of CHX10-positive retinal 
progenitors was observed. The appearance of BRN3-expressing RGCs could be observed 
shortly thereafter, followed by the onset of recoverin-positive photoreceptor-like cells. RT-
PCR analysis further confirmed this stepwise pattern of retinal fate determination (Figure 
2B).
Characterization and Functional Analysis of hPSC-Derived Retinal Ganglion Cells
The expression of BRN3, along with the differentiation of hPSCs through the stepwise 
process of retinal differentiation, aids in the identification of resultant RGCs. Overall, 
approximately 36.1 ± 1.7% of cells expressed the RGC-associated transcription factor BRN3 
within the first 40 days of differentiation (Figure 3A). Beyond the expression of BRN3, 
however, a variety of other features are associated with the development of RGCs. Upon 
differentiation, presumptive RGCs co-expressed a wide array of such factors associated with 
RGC specification (Figure 3B-E). Furthermore, maturation and morphological changes of 
these cells were readily observed, as BRN3-positive RGCs were found associated with 
Ohlemacher et al. Page 6
Stem Cells. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
MAP2-positive neurite extensions (Figure 3F). Interestingly, a small population of 
melanopsin-expressing cells were observed, indicative of intrinsically photosensitive retinal 
ganglion cells (ipRGCs). These cells expressed high levels of melanopsin (Figure 3G) and 
largely lacked BRN3 expression (Figure 3G’), typical of the M1 class of ipRGCs49-51.
The ability to exhibit lengthy neurite outgrowths is a further characteristic of RGCs when 
compared to other neurons of the retina. Following prolonged growth in vitro, extensive 
neurite outgrowth was readily observed from BRN3-expressing RGCs (Figure 3H). 
Cytoskeletal components became compartmentalized with clear separation of MAP2 
expression in somatodendritic regions and Tau expression confined to axonal extensions that 
fasciculated and extended over long distances. The progressive acquisition of RGC 
characteristics, as well as the differential expression of these characteristics apart from non-
retinal forebrain cells, was further characterized by qRT-PCR analysis (Figure 3I-J). In 
comparison to retinal progenitor cells identified at earlier stages of differentiation, RGC 
populations exhibited a robust increase in the expression of RGC-associated genes, along 
with a significant decrease in the expression of retinal progenitor-associated genes (Figure 
3I). Furthermore, when compared to age-matched non-retinal forebrain populations as 
indicated above (Figure 1A), a significant increase was observed in the expression of retinal 
and RGC-associated genes (Figure 3J).
As projection neurons connecting the eye with the brain, and unlike most other neurons of 
the retina, RGCs transmit visual information via elicitation of action potentials through the 
use of voltage-gated ion channels29. To confirm whether hPSC-derived RGCs are capable of 
similar physiological activity, prospective RGCs were first morphologically identified for 
electrophysiological analysis based upon extensive neurite outgrowth (Figure 4A) typical of 
these cells 15,52,53. Electrophysiological activity of hPSC-derived RGCs was then analyzed 
by patch clamp analysis, and recorded cells were filled with Lucifer Yellow for subsequent 
immunocytochemical analysis for BRN3 expression to definitively identify analyzed cells as 
RGCs (Figure 4B). hPSC-derived RGCs demonstrated the ability to fire action potentials 
(Figure 4C) and exhibited a hyperpolarized resting membrane potential (Figure 4D). These 
electrophysiological properties were associated with ionic currents, including outward flow 
that could be blocked by the addition of TEA, indicating the presence of voltage-gated K+ 
channels (Figure 4E), as well as inward current flow that was sensitive to the voltage-gated 
Na+ channel blocker TTX (Figure 4F). Furthermore, both K+ and Na+ ionic currents were 
shown to be voltage-dependent in nature.
In Vitro Modeling of Optic Neuropathies Using Patient Specific iPSCs
The ability to derive RGCs from an hPSC source has important implications beyond studies 
of developmental biology1,2, including translational applications3-5,7 such as in vitro disease 
modeling and pharmacological screening54-56 when derived from specific patient sources. 
Mutations in the OPTN gene have been extensively documented to result in severe RGC 
degeneration associated with primary open angle glaucoma30-35 and therefore, should 
provide an effective in vitro tool for studies of underlying disease mechanisms, as well as 
subsequent pharmacological screening. To this end, skin fibroblasts from a patient 
possessing an E50K missense mutation in the OPTN gene were reprogrammed to 
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pluripotency, exhibiting robust expression of a full complement of pluripotency-associated 
factors (Figure S2) and the ability to give rise to cell types of all three germ layers (Figure 
S3).
Upon differentiation, enriched populations of OPTN iPSC-derived retinal neurospheres 
(Figure 5A) were characterized by robust expression of CHX10 (Figure 5B), indicative of a 
retinal progenitor state4,39,57. Subsequent differentiation of these retinal progenitors yielded 
BRN3-positive cells that could be definitively identified as RGCs due to their retinal lineage. 
These RGCs exhibited elaborate MAP2-positive neuronal morphologies and formation of 
complex neural networks (Figure 5C-D). Undifferentiated OPTN iPSCs exhibited a 
disorganized Golgi morphology that led to a significant increase in size (Figure S4A-C), as 
previously reported32,33,42. Interestingly, however, differentiation to the affected RGC 
phenotype yielded no significant difference in the size and organization of the Golgi of 
OPTN RGCs compared to control RGCs (Figure S4D-F).
To further examine the applicability of OPTN iPSC-derived RGCs as an in vitro model for 
glaucoma, the activation of caspase-3 was analyzed and quantified via 
immunocytochemistry in comparison to unaffected control lines. In undifferentiated 
cultures, little activation of caspase-3 was observed and no significant differences were seen 
between control and OPTN iPSCs (Figure 5E-G). Upon differentiation of these cells to the 
affected RGC cell type, caspase-3 activation was minimal in control iPSC-derived RGCs but 
was significantly increased in OPTN iPSC-derived RGCs (Figure 5H-J). Given these 
increased levels of apoptosis, the ability of these cells to serve as a tool for pharmacological 
screening was subsequently tested, utilizing factors previously identified as neuroprotective 
in other systems58-63. Upon treatment of OPTN iPSC-derived RGCs with either BDNF or 
PEDF, a significant reduction in caspase-3 activation was observed (Figure 5K-M).
Discussion
The results presented here demonstrate the robust derivation and definitive identification of 
RGCs from hPSCs as identified by the combination of morphological, phenotypic, and 
physiological measures. Furthermore, these efforts were applied to establish an in vitro 
model of glaucoma with patient-derived iPSCs, allowing for the ability to study associated 
underlying features of the disease itself, as well as the potential use as a tool for 
pharmacological screening54.
Although previous reports have demonstrated that hPSCs can acquire retinal characteristics 
upon differentiation4,12-20,25, including features of retinal ganglion cells4,12-18,24-28, many 
markers used to identify RGCs, particularly BRN3, are also expressed in other neural cells, 
including some auditory neurons45 as well as somatosensory neurons46. Thus, efforts to 
unequivocally assign an RGC identity are complicated without thorough and systematic 
characterization. Moreover, BRN3 exists in three different forms, namely BRN3A, BRN3B, 
and BRN3C64,65. While the current studies analyzed the overall expression of BRN3, it is 
likely that most of the cells expressed BRN3B, as this form is known to play a critical role in 
the differentiation and survival of RGCs, and is also known to be expressed earlier in 
development than other forms of BRN3.
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In the current study, multiple approaches were undertaken to ensure that presumptive RGCs 
had indeed adopted this fate. First, retinal differentiation proceeded through a retinal 
progenitor stage that could be readily identified and isolated, yielding highly enriched 
populations of CHX10-expressing retinal progenitor cells, with subsequent expression of 
BRN3 allowing for more definitive identification of RGCs. Additionally, BRN3 expression 
was often found expressed in close association with other retinal cell types, while expression 
of markers associated with auditory and somatosensory lineages was not observed. Thus, the 
data presented provides the strongest evidence to date of the ability to conclusively 
differentiate RGCs from hPSCs.
Intrinsically photosensitive retinal ganglion cells (ipRGCs) are a specific subtype of RGC 
that function in non-visual phototransduction processes including circadian entrainment and 
pupillary responses49-51. The data presented within the current study is the first to 
demonstrate the differentiation of ipRGCs from hPSCs, as detected by the expression of the 
phototransduction protein melanopsin. While the derivation of these cells was exceedingly 
rare, the presence of these cells allows for future investigation into the developmental 
specification of ipRGCs, as well as studies analyzing the damage and loss of ipRGCs in a 
variety of injuries and degenerative disorders of the retina66.
Beyond phenotypic features, these hPSC-derived RGCs also possessed appropriate 
morphological and physiological features. After prolonged growth in vitro, hPSC-derived 
RGCs were capable of extensive neurite outgrowth, which was specifically directed toward 
other aggregates of cells, perhaps due to paracrine signaling. Further maturation of hPSC-
derived RGCs was also observed in the compartmentalization of MAP2 and Tau, 
cytoskeletal proteins that are found widely expressed in immature neurons but whose 
expression becomes confined to somatodendritic and axonal regions, respectively, in mature 
neurons
67
. Furthermore, these cells exhibited the ability to function physiologically, with the 
ability to conduct sodium and potassium through voltage-dependent channels as well as the 
ability to fire action potentials. Although these features are characteristic of many types of 
neurons
29
, in the retina these characteristics are specifically found within the RGCs as well 
as a subset of amacrine cells. While these cells exhibited a hyperpolarized resting membrane 
potential, this potential was recorded at an average of approximately −40 mV, indicating that 
these cells have not yet reached a fully mature state. Future experiments will necessitate the 
development of methods by which these hPSC-derived RGCs can be induced to mature 
further in vitro.
Beyond the differentiation and characterization of hPSC-derived RGCs, efforts were also 
focused on the development of iPSC-based models of optic neuropathies. Glaucoma is the 
most prevalent of the optic neuropathies, with a current incidence of more than 60 million 
individuals worldwide22,23. However, a variety of factors exist which are causative or at least 
associated with the onset of glaucomatous neurodegeneration68,69. Mutations in the OPTN 
gene were selected for study, particularly the E50K mutation which has been previously 
demonstrated to result in a particularly severe neurodegenerative phenotype30-32. While the 
results obtained with these cells will be of significance for future studies of this glaucoma-
associated genotype, these results could also prove to be more profound for other glaucoma 
phenotypes as well. As other factors such as elevated intraocular pressure have been 
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suggested to serve as a trigger for subsequent degeneration of RGCs69, mutations in genes 
including OPTN could provide a similar trigger, with downstream effects mimicking 
features of glaucoma common to many underlying causes.
Whereas previous studies have analyzed features of glaucoma in RGCs by utilizing animal 
models or non-affected cell types in vitro42,70,71, the development of a human induced 
pluripotent stem cell model of glaucoma allows for precise analysis of the affected cell type. 
The ability to study features of the disease process in human cells from the affected cell type 
is of utmost importance, as some previous studies have identified disruptions in the Golgi 
complex as a hallmark of certain mutations in OPTN, including the E50K mutation32,33,42. 
While this phenotype was recapitulated in undifferentiated OPTN iPSCs, this Golgi 
fragmentation was not observed upon differentiation to RGCs, the cell type directly affected 
by the disease process. It is not completely surprising that the Golgi phenotype changed 
following differentiation, as previous studies have demonstrated that the shape and size of 
the Golgi complex can, and indeed often does, vary from one type of cell to another72,73. 
The size and shape of the Golgi complex are often larger in those cells that have greater 
intracellular trafficking demands, particularly those that are mitotically active such as 
undifferentiated hPSCs. This is reflected in the fact that the Golgi size was markedly larger 
in the undifferentiated state compared to differentiated RGCs, regardless of whether the cells 
were from control or E50K sources. Thus, there is not necessarily any reason to expect that 
differences between cell sources in the undifferentiated state will be maintained at later 
stages of differentiation. In fact, the data presented strongly suggests that differences in 
Golgi morphology do not likely contribute to increased caspase-3 activation observed in 
OPTN E50K cells. Thus, disruptions to the Golgi complex may not have any direct 
connection to the health and survival of RGCs and consequently, may not play a role in 
glaucomatous neurodegeneration observed in patient samples. Such a result underscores the 
importance of iPSC-based models of inherited diseases and the ability to differentiate these 
cells to the affected cell type. The increased apoptosis observed in OPTN cells appeared to 
be specific for RGCs, the affected cell type, as no significant differences were observed in 
undifferentiated OPTN iPSCs compared to control cell lines. As such, the development of 
this in vitro model of glaucoma will allow for future studies analyzing precise mechanisms 
underlying glaucomatous neurodegeneration. The results of these studies also highlight the 
potential of iPSCs to serve as a tool for pharmacological screening54-56, as treatment of 
OPTN iPSC-derived RGCs with either BDNF or PEDF was able to partially rescue these 
cells from apoptosis. Interestingly, treatment with these neuroprotective factors yielded 
similar levels of cell survival. While the reason for this similarity is not known, the 
possibility exists for overlap in these two signaling pathways. While both BDNF and PEDF 
are known to inhibit the apoptotic pathway59-61,63, they also affect transcription through 
MEK/ERK signaling pathways58. Thus, the similar net effects produced by BDNF and 
PEDF could be due to convergence of these signaling pathways within the cell.
Conclusion
Taken together, the results of the current study represent the most comprehensive description 
of RGC derivation from an hPSC source by morphological, phenotypic, and functional 
parameters, as well as the ability to utilize these approaches for studies of optic neuropathies 
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such as glaucoma. On a broader level, this study establishes the suitability of hPSCs to 
analyze critical stages of RGC development from a human source. Furthermore, these results 
demonstrate the applicability of hPSC-derived RGCs for disease modeling and 
pharmacological screening for a host of optic neuropathies, both complementing existing 
animal models as well as narrowing the gap to clinical applications.
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Refer to Web version on PubMed Central for supplementary material.
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Fig 1. 
Definitive identification of presumptive RGCs using BRN3 expression in differentiated 
cultures of hPSCs. After 25 days of differentiation, two morphologically distinct populations 
of neurospheres were observed (A), from which optic vesicle-like neurospheres were 
identified and isolated based upon their phase-bright appearance (B). Isolated optic vesicle 
neurospheres were highly enriched for CHX10-expressing retinal progenitor cells (C). After 
a total of 40 days of differentiation, RT-PCR analysis demonstrated that presumptive RGCs 
expressed BRN3 in conjunction with other retinal markers, but not markers of other BRN3-
expressing lineages (D). Genomic DNA (Gen.) served as a positive control for RT-PCR 
experiments. Immunocytochemical analysis confirmed expression of BRN3 localized with 
other retinal markers (E-G). Images were captured at timepoints of 30 days of differentiation 
in A-C, 50 days of differentiation in E-F, and 70 days of differentiation in G. Scale bars 
equal 500 μm in A-B, 100 μm in C, and 50 μm in D-F.
Ohlemacher et al. Page 15
Stem Cells. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig 2. 
hPSC-derived RGCs are generated in a temporally appropriate sequence. 
Immunocytochemistry analysis revealed that BRN3-positive RGCs appeared subsequent to 
the establishment of neural (PAX6) and retinal (CHX10) progenitor fates, but prior to the 
generation of photoreceptor-like (Recoverin) cells (A). qRT-PCR analysis confirmed that 
genes associated with retinal and RGC development were expressed at developmentally-
appropriate timepoints, with those genes associated with retinal progenitors expressed prior 
to the onset of RGC-specific genes (B). Scale bar equals 50 μm.
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Fig 3. 
Phenotypic characterization of hPSC-derived RGCs. After 40 days of differentiation, BRN3-
positive RGCs comprised approximately 36.1 ± 1.7% of the total differentiated population 
(A). BRN3-positve RGCs expressed numerous RGC-associated markers (B-E), and began to 
extend MAP2-positive neurites (F) within a total of 50-70 days of differentiation. A small 
subset of intrinsically photosensitive melanopsin-positive RGCs were observed that were 
BRN3-negative (G-G’) by 70 days of differentiation. Prolonged differentiation of hPSC-
derived RGCs eventually gave rise to elaborate RGC-like morphologies exhibiting 
compartmentalized expression of MAP2 and TAU, including fasciculated TAU-positive 
axons (H) within 100 total days of differentiation. qRT-PCR analysis revealed that BRN3-
expressing cultures exhibited significantly increased expression of RGC-associated 
transcripts compared to their retinal progenitor precursors (I), as well as their age-matched 
non-retinal forebrain counterparts (J). Significant differences indicated as * = p<0.05, ** = 
p<0.01, *** = p<0.005, **** = p<0.001. Scale bars equal 200 μm in A, 25 μm in B-F, and 
10 μm in G-H.
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Fig 4. 
Physiological analysis of hPSC-derived RGCs. Patch clamp analysis was performed and 
retinal ganglion cell morphologies were highlighted by DIC microscopy, including long 
neurite outgrowth in RGCs derived between 80-90 total days of differentiation (A). 
Recorded cells were filled with Lucifer Yellow for subsequent immunocytochemical 
confirmation of their RGC identity (B). hPSC-derived RGCs demonstrated the ability to fire 
action potentials (C) and exhibited a hyperpolarized resting membrane potential (D). These 
features were associated with the conductance of potassium and sodium through voltage-
gated channels, which could be blocked by the addition of either TEA (E) or TTX (F).
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Fig 5. 
Patient-derived hPSCs can be utilized as an effective model of RGC neurodegeneration. 
Normal tension glaucoma patient fibroblasts, due to a mutation in the OPTN gene, were 
directed to differentiate to a retinal progenitor fate (A) as characterized by extensive 
expression of CHX10 (B) by a total of 30 days of differentiation. Retinal ganglion cells were 
subsequently differentiated and characterized by the expression of BRN3 as well as the 
development of complex neural networks, indicated by MAP2 (C) and mGluR2 (D) at 70 
days of differentiation. In the pluripotent state, control and OPTN hPSCs exhibited no 
significant differences in apoptosis (E-G). Following differentiation for 70 days, OPTN 
RGCs demonstrated significantly increased apoptosis (H-J), which could be significantly 
reduced by treatment with select neuroprotective factors (K-M). Significant differences 
indicated as * = p<0.05, *** = p<0.005. Scale bars equal 400 μm in A, 100 μm in B, 50 μm 
in C-F, and 25 μm in H-L.
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